Allergic disorders, as asthma, allergic rhinitis/rhinoconjunctivitis, atopic dermatitis, food allergies
and anaphylaxis have an increasing burden in the general population and a growing body of
evidence has shown that an increased interest has aroused to seek for more effective treatment strategies.
Conventional pharmacotherapy by antihistamines, anti-leukotrienes, corticosteroids and bronchodilators
can routinely control most of the cases, in addition to allergen avoidance which saves the
date. Furthermore, allergen specific immunotherapy stands as the only curative method to treat the underlying
cause of allergic immune response by induction of immune tolerance. However, response to pharmacotherapies
can show diversity depending on the genotype and phenotype of the allergic disorders, which are known to be under the
influence of multifactorial triggers. Thus, understanding the mechanisms of development of allergic disorders, in addition
to selective description of the phenotypes can provide access to development of more specific therapies in order to control
the disease progression. Monoclonal antibodies can be the major actors in this targeting process. Concerns about the
safety, efficacy and long-term tolerability of these molecules always stand as a question for them, in order to gain indications
for the treatment of allergic disorders. This review includes most recent developments and patents on usage of
monoclonal antibodies for the treatment of allergic disorders.